Our Insights Oncology Anthony Iannacci 7/14/26 Oncology Anthony Iannacci 7/14/26 Cogent’s bezuclastinib reduces risk of disease progression or death by 50% in 2L metastatic GIST when combined with standard of care Read More
Oncology Anthony Iannacci 7/14/26 Oncology Anthony Iannacci 7/14/26 Cogent’s bezuclastinib reduces risk of disease progression or death by 50% in 2L metastatic GIST when combined with standard of care Read More
